examined highly differentiated CD28- CD27- CD4 T (THD) cells using FACS in the peripheral blood of 34 patients with NSCLC both prior to starting and during PD-1/PD-L1 inhibitor treatment. This evidence concerns the gene CD274 and non-small cell lung carcinoma.